TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04049552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin 8% Ointment
Description: A compounded ointment containing 8% rapamycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Petrolatum ointment placebo
Study: NCT05737329

Intervention type: DRUG
Group type: OTHER
Intervention: Transdermal estradiol gel 0.1% 1.5mg/ day
Description: Estradiol gel 0.1% 1.5mg/ daily + Micronized Progesterone 200mg

Intervention type: DRUG
Group type: OTHER
Intervention: Transdermal estradiol gel 0.1% 1.5mg/ day
Description: Estradiol gel 0.1% 1.5mg/ daily + Micronized Progesterone 200mg

Intervention type: DRUG
Group type: OTHER
Intervention: Transdermal estradiol gel 0.1% 2.0mg/ day
Description: Estradiol gel 0.1% 2.0mg/ daily + Micronized Progesterone 200mg

Intervention type: DRUG
Group type: OTHER
Intervention: Transdermal estradiol gel 0.1% 2.0mg/ day
Description: Estradiol gel 0.1% 2.0mg/ daily + Micronized Progesterone 200mg
Study: NCT00036777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02456233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional AF Ablation with PVI
Description: Trigger Based Ablation for AF, using Pulmonary Vein Isolation (PVI) alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM-guided ablation plus PVI
Description: Substrate ablation for AF, via ablation of rotors and focal sources. Conventional (PVI) ablation will also be performed.
Study: NCT01859390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AquADEKs-2
Description: AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control multivitamin
Description: The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control multivitamin
Description: The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
Study: NCT01448031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsule ASA 81mg/esomeprazole 20mg
Description: Multiple doses administered on Day 1 to 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylzuur Apotex Cardio
Description: Multiple doses administered on Day 1 to 5
Study: NCT04189276

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ETV/TDF+T101 No.1
Description: Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ETV/TDF+T101 No.2
Description: Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ETV or TDF
Description: Patients will be administrated ETV or TDF once each day successively until Day420.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ETV/TDF+Peg-IFNα-2b
Description: Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
Study: NCT04621942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inertial rehabilitation
Description: Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Exercises were conducted by the same 2 researchers. Each training session included warm-up and 4 sets of shoulder ﬂexors, extensors, abductors, and adductors, with the right and left arms worked separately (16 sets for left and 16 sets for right arm). Each set lasted 15 seconds, a 2-minute break occurred between consecutive sets (without rest period between right and left arm). For all trained muscles 5 kg load was applied. During the training participants developed 70% of their maximal force achieved during the strength measurement. Participants observed developed during training force value displayed on-line on the screen. Cyklotren software allows to set the upper and lower limit of force; when developed strength was to low or to high a beep signal was emitted to correct participant force.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gymnastic rehabilitation
Description: All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gymnastic rehabilitation
Description: All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.
Study: NCT01881100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish
Description: All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluoride varnish
Description: All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
Study: NCT01249339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 1g, single dose. One pouch administered over 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 1g, single dose. One pouch administered over 30 minutes.
Study: NCT01821469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Bipolar disorders are educated to learn about their pathology
Study: NCT01740674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic data collection
Study: NCT01750138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose powder
Study: NCT03827954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HeartMapp+CT
Description: HeartMapp+CT is a mobile system that includes physiological modules that support self-monitoring and exercises that promote heart health, and computerized plasticity-based adaptive cognitive training modules that train participants to enhance cognitive functions and ultimately heart failure outcomes.
Study: NCT04396834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Oral Tablet
Description: Lorcasering 10mg Oral Tablet (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo Oral Tablet (BID)
Study: NCT04390737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH2853 Tablets
Description: Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
Study: NCT03747926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: single-rising oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-rising oral dose
Study: NCT05308251

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein Mesh Hernioplasty
Description: The inguinal canal was opened and the hernia sac was dissected from the spermatic cord The deep inguinal ring was tightened with one or two polypropylene 2/0 sutures. The posterior wall of the inguinal canal was supported using the standard polypropylene mesh and fixed with 2/0 polyproline. The ilioinguinal nerve, iliohypogastric nerve, and genital branch of the genitofemoral nerve were preserved and care was taken to prevent entrapment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein Mesh Hernioplasty
Description: The inguinal canal was opened and the hernia sac was dissected from the spermatic cord The deep inguinal ring was tightened with one or two polypropylene 2/0 sutures. The posterior wall of the inguinal canal was supported using the standard polypropylene mesh and fixed with 2/0 polyproline. The ilioinguinal nerve, iliohypogastric nerve, and genital branch of the genitofemoral nerve were preserved and care was taken to prevent entrapment.
Study: NCT01249339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
Study: NCT03367026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine Oral Product
Description: Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.~Day 1 :~2.5 mg ivabradine b.i.d. if heart rate ≥90 bpm~Day 2,3,4:~2.5 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm. 5.0mg ivabradine b.i.d. if heart rate ≥90bpm
Study: NCT01237093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1. Meat, no fish or soda
Description: weight maintaining diet with meat but no fish or soda

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2. Meat and soda, no fish
Description: weight maintaining diet with meat and soda but no fish

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3. Meat and fish, no soda
Description: weight maintaining diet with meat and fish but no soda

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4. Meat and fish and soda
Description: weight maintaining diet with meat, fish and soda

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5. Fish, no meat or soda
Description: weight maintaining diet with fish but no meat or soda

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6. Fish and soda, no meat
Description: weight maintaining diet with fish and soda but no meat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7. No meat, fish or soda
Description: weight maintaining diet with no meat, no fish, and no soda (vegetarian)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8. Soda, no meat or fish
Description: weight maintaining diet with soda but no meat or fish (vegetarian + soda)
Study: NCT03716713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CeraShield Endotracheal Tube
Description: Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT
Study: NCT01349569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Myeloma Vaccine
Description: A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar-13
Description: Prevnar-13 will be administered at 0.5ml dose by intramuscular injection at the same time as GVAX vaccine.
Study: NCT04898101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microtracer [14C]ACP-196
Description: Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microtracer [14C]ACP-196
Description: Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.
Study: NCT04592523

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT00945425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: oral capsule, once or twice daily, 7 days
Study: NCT02048943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib lactate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00945425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: oral capsule, once or twice daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: oral capsule, once or twice daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: oral capsule, once or twice daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral capsule, once or twice daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral capsule, once or twice daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral capsule, once or twice daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral capsule, once or twice daily, 7 days
Study: NCT00549198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine and efavirenz

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine and efavirenz
Study: NCT02938494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-123 Lotion
Description: Lotion
Study: NCT04165317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guerin
Description: Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin
Description: Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin
Description: Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
Study: NCT00626522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide and formoterol
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide and formoterol
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide and formoterol
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aclidinium bromide and formoterol placebo
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aclidinium bromide and formoterol placebo
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aclidinium bromide and formoterol placebo
Description: once daily
Study: NCT03618238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12 mg daily for continus 14 days every 21 days
Study: NCT00414700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChondroCelect implantation
Description: 10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm².
Study: NCT02938494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac Cream
Description: Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Lotion
Description: Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Cream
Description: Cream
Study: NCT00739479

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss
Description: Participants will reduce their total dietary intake by \~800 kcal/day. \~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of \~700 kcal/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Weight Loss
Description: Participants will reduce their total dietary intake by \~800 kcal/day. \~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of \~700 kcal/day.
Study: NCT01451905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
Study: NCT05343949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT exercise program ABC
Description: Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT exercise program CAB
Description: Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIIT exercise program BCA
Description: Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
Study: NCT02062606

Intervention type: DEVICE
Intervention: MESA Rail™ Deformity System
Description: MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
Study: NCT03521999

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AboutFace
Description: AboutFace is an online peer-to-peer digital storytelling resource for Veterans with PTSD. Veterans will have access to AboutFace while they are enrolled in PTSD specialty care through the Charleston PCT.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care (eUC)
Description: Enhanced Usual Care (eUC) includes access to a PTSD educational brochure. Veterans will have access to the brochure information while they are enrolled in PTSD specialty care through the Charleston PCT.
Study: NCT02517710

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stratafix synthetic barbed suture
Description: hysterotomy closure in Cesarian section

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stratafix synthetic barbed suture
Description: hysterotomy closure in Cesarian section
Study: NCT01374399

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise and relaxation
Description: resistance and endurance exercise, 3-5 times per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise and relaxation
Description: resistance and endurance exercise, 3-5 times per week
Study: NCT02415959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon IR